PART VI. DRUG PRODUCT SELECTION
§328-91 Definitions. As used in this part:
"Agent" means a person under the direct supervision of a pharmacist, acting in the pharmacist's presence.
"Bioequivalents" means chemical equivalents which, when administered to the same individuals in the same dosage regimen, will result in comparable bioavailability, as defined by the Federal Food and Drug Administration.
"Board" means the drug product selection board.
"Equivalent drug product" means a drug product with the same established name, active ingredient strength, quantity, and dosage form as the drug product identified in the prescription, and listed as therapeutically equivalent in the current state drug formulary.
"Established name" has the meaning given in section 502(e)(3) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. 352(e)(3)).
"Hawaii additions and deletions list" means:
(1) A list of drug products that the board has determined to be safe, effective, and therapeutically equivalent generic drug products but are not in the Orange Book; and
(2) A list of drug products that are included in the Orange Book, but the board has determined not to be safe, effective, therapeutically equivalent, or bioequivalent generic drug products.
"Orange Book" means the United States Food and Drug Administration's "Approved Drug Products with Therapeutic Equivalence Evaluations" publication and its cumulative supplements, which include a list of approved prescription drug products with therapeutic equivalence evaluations. [L 1980, c 187, pt of §1; am L 1982, c 122, §1(3); am L 1996, c 209, §2; am L 1997, c 214, §10; am L 1999, c 209, §1]